Su Cheng, Lv Yufang, Lu Wenhao, Yu Zhenyuan, Ye Yu, Guo Bingqian, Liu Deyun, Yan Haibiao, Li Tianyu, Zhang Qingyun, Cheng Jiwen, Mo Zengnan
Department of Urology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Front Oncol. 2021 Oct 14;11:719564. doi: 10.3389/fonc.2021.719564. eCollection 2021.
Renal cell carcinoma (RCC) is the most common type of kidney cancer. Studying the pathogenesis of RCC is particularly important, because it could provide a direct guide for clinical treatment. Given that tumor heterogeneity is probably reflected at the mRNA level, the study of mRNA in RCC may reveal some potential tumor-specific markers, especially single-cell RNA sequencing (scRNA-seq).
We performed an exploratory study on three pathological types of RCC with a small sample size. This study presented clear-cell RCC (ccRCC), type 2 pRCC, and chRCC in a total of 30,263 high-quality single-cell transcriptome information from three pathological types of RCC. In addition, scRNA-seq was performed on normal kidneys. Tumor characteristics were well identified by the comparison between different pathological types of RCC and normal kidneys at the scRNA level.
Some new tumor-specific markers for different pathologic types of RCC, such as and were identified and validated. We also discovered that both highly expressed in tumor cells of ccRCC and type 2 pRCC. The presence of two different types of endothelial cells in ccRCC and type 2 pRCC was also identified and verified. An endothelial cell in ccRCC may be associated with fibroblasts and significantly expressed fibroblast markers, such as and . At last, by applying scRNA-seq results, the activation of drug target pathways and sensitivity to drug responses was predicted in different pathological types of RCC.
Taken together, these findings considerably enriched the single-cell transcriptomic information for RCC, thereby providing new insights into the diagnosis and treatment of RCC.
肾细胞癌(RCC)是最常见的肾癌类型。研究RCC的发病机制尤为重要,因为它可为临床治疗提供直接指导。鉴于肿瘤异质性可能在mRNA水平上得到体现,对RCC中的mRNA进行研究可能会揭示一些潜在的肿瘤特异性标志物,尤其是单细胞RNA测序(scRNA-seq)。
我们对三种病理类型的RCC进行了小样本量的探索性研究。本研究呈现了来自三种病理类型RCC的共30263条高质量单细胞转录组信息,包括透明细胞RCC(ccRCC)、2型乳头状RCC(pRCC)和嫌色细胞RCC(chRCC)。此外,对正常肾脏进行了scRNA-seq。通过在scRNA水平上比较不同病理类型的RCC与正常肾脏,很好地识别了肿瘤特征。
鉴定并验证了一些针对不同病理类型RCC的新的肿瘤特异性标志物,如 和 。我们还发现 在ccRCC和2型pRCC的肿瘤细胞中均高表达。在ccRCC和2型pRCC中还鉴定并证实了两种不同类型内皮细胞的存在。ccRCC中的一种内皮细胞可能与成纤维细胞有关,并显著表达成纤维细胞标志物,如 和 。最后,通过应用scRNA-seq结果,预测了不同病理类型RCC中药物靶标途径的激活情况以及对药物反应的敏感性。
综上所述,这些发现极大地丰富了RCC的单细胞转录组信息,从而为RCC的诊断和治疗提供了新的见解。